Biohaven's High Risk Bet Pays Off in a Big Way Biohaven's recent deal with SK Biopharmaceuticals appears to be a straightforward licensing agreement, but it conceals a complex web of financial incentives that reflect the increasingly fraught relationship between pharmaceutical companies and their investors.
On one hand, this partnership provides much needed cash for Biohaven's pipeline, while on the other, it cedes control over its most promising asset.
The $795 million deal is a coup for Biohaven, particularly given the company's precarious financial situation.